The New Drug Applications for Reproxalap, Linerixibat, Kresladi, and LNTH-2501 await the FDA decision in March. For Kresladi, this marks a second bid for approval, while Reproxalap is making its third attempt. The path to FDA approval is often challenging for many drug candidates. Meanwhile, approved therapies Sotyktu and Imcivree await decisions on label expansions, which could broaden their commercial reach, potentially driving higher sales.